E. F. Bleiler

Everett Franklin Bleiler (April 30, 1920 – June 13, 2010) was an editor, bibliographer, and scholar of science fiction, detective fiction, and fantasy literature. In the late 1940s and early 1950s, he co-edited the first "year's best" series of science fiction anthologies, and his Checklist of Fantastic Literature has been called "the foundation of modern SF bibliography". Among his other scholarly works are two Hugo Award–nominated volumes concerning early science fiction—Science-Fiction: The Early Years and Science-Fiction: The Gernsback Years—and the massive Guide to Supernatural Fiction.

Bleiler worked at Dover Publications from 1955, becoming executive vice-president of the company from 1967 until he left in 1977; he then worked for Charles Scribner's Sons until 1987. He edited a number of ghost story collections for Dover, containing what the genre historian Mike Ashley has described as "detailed and exemplary introductions".

Bleiler received the Pilgrim Award for lifetime achievement in science fiction scholarship in 1984, the World Fantasy Award for Life Achievement in 1988, the First Fandom Hall of Fame award in 1994, and the International Horror Guild Living Legend award in 2004.

EF

EF or ef may refer to:

Computing

Culture

Linguistics

Organizations

Psychology

Science

Efavirenz

Efavirenz (EFV), sold under the brand names Sustiva among others, is a non-nucleoside reverse transcriptase inhibitor (NNRTI). It is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, the United States Department of Health and Human Services Panel on Antiretroviral Guidelines currently recommends the use of efavirenz in combination with tenofovir/emtricitabine (Truvada) as one of the preferred NNRTI-based regimens in adults and adolescents. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to reduce the risk of HIV infection in people exposed to a significant risk (e.g. needlestick injuries, certain types of unprotected sex etc.).

It is usually taken on an empty stomach at bedtime to reduce neurological and psychiatric adverse effects.

Efavirenz was combined with the HIV medications tenofovir and emtricitabine, all of which are reverse transcriptase inhibitors. This combination of three medications under the brand name Atripla, provides HAART in a single tablet taken once a day.

E2F4

Transcription factor E2F4 is a protein that in humans is encoded by the E2F4 gene.

Function

The protein encoded by this gene is a member of the E2F family of transcription factors. The E2F family plays a crucial role in the control of cell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses. This protein binds to all three of the tumor suppressor proteins pRB, p107 and p130, but with higher affinity to the last two. It plays an important role in the suppression of proliferation-associated genes, and its gene mutation and increased expression may be associated with human cancer.

Structure

The E2F proteins contain several evolutionally conserved domains found in most members of the family. These domains include a DNA binding domain, a dimerization domain which determines interaction with the differentiation regulated transcription factor proteins (DP), a transactivation domain enriched in acidic amino acids (Asp + Glu), and a tumor suppressor protein association domain which is embedded within the transactivation domain.